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BiomarkerRitonavir is a protease inhibitor associated with metabolic abnormalities and cardiovascular disease. We
have investigated the effects of low-dose ritonavir treatment on gene expression in peripheral blood
mononuclear cells (PBMC) of 10 healthy donors. Results using whole genome Illumina microarrays show
that ritonavir modulates a number of genes implicated in lipid metabolism, inﬂammation and
atherosclerosis. These candidate genes are dual speciﬁcity phosphatase 1 DUSP1), Kelch domain containing
3 (KLHDC3), neutral cholesterol ester hydrolase 1 (NCEH1) and acyl-CoA synthetase short-chain family
member 2 (ACSS2). Validation experiments using quantitative PCR showed that ritonavir (at 100 mg once
daily and 100 mg twice daily signiﬁcantly down-regulated these 4 selected candidate genes in 20 healthy
individuals. Lower expression levels of these 4 candidate genes, known to play a critical role in inﬂammation,
lipid metabolism and atherosclerosis, may explain ritonavir adverse effects in patients.King's College London, 3.38
SE1 9NH, UK. Fax: +44 020
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
In the treatment of Human immunodeﬁciency virus (HIV) infected
patients, protease inhibitors (PI) inhibit catalytic activity of HIV aspartyl
protease leading to the production of immature, non-functional viral
particles. There are currently 10 approved PI used forHIV therapy [1]. The
PI ritonavir, initially prescribed at therapeutic doses (600 mg twice daily),
was associated with important side effects [2]. It is nowadays used at
lower doses (e.g. 100 mg once or twice daily) as a pharmacokinetic (PK)
booster in combinationwitha secondPI [3]. Administrationof therapeutic
doses of ritonavir has been associated with metabolic abnormalities and
cardiovascular disease [4]. Also, low-dose ritonavir has been shown to
increase cholesterol, low-density lipoprotein (LDL) triglycerides and to
decrease high-density lipoprotein (HDL) over 2 weeks in healthy
volunteers [5,6]. Due to the complexity of interactions and number of
pathways implicated, the causes and mechanisms are still unclear.
Moreover, it is not clear if HIV infection per se is implicated in someof side
effects experienced by HIV-infected individuals on antiretroviral therapy.
Geneexpression studies, usingwhole genomemicroarrays in tandem
with bioinformatics and validation by real time quantitative PCR (Q-PCR)are increasingly being used in investigating vascular, inﬂammatory,
metabolic diseases and the pharmacogenomics of therapeutic drugs. The
molecular effects of ritonavir has been investigated on 3T3-L1 murine
adipocytes [7,8], human osteoblast [9], human hepatocytes [8] and on
murine liver [10]. However, very little is yet known on the role and/or
action of ritonavir. In this study, we have investigated using whole
genome Illuminamicroarrays, the effects of low-dose ritonavir treatment
on peripheral blood mononuclear cells (PBMC) of 10 healthy donors.
Results have allowed us to identify differentially expressed genes and
affected biological function pathways.
Results
Microarrays data were analysed to identify candidate genes using 3
different algorithms. Moreover, functional class scoring was performed
to identify alterations in key cellular functions induced by ritonavir.
Selected candidates genes were further validated by Q-PCR. Pathway
analysis was performed to identify genes that link the validated
candidate genes.
Candidate genes
Normalised microarray data were analysed by using three
different algorithms (Random-variance t-test, SAM and ANOVA).
Each of the three algorithms gave a list of signiﬁcantly modulated
Table 1
Thirty six candidate genes modulated in PBMC by ritonavir.
Gene symbol Genes description Parametric p-value Permutation p-value Intensities ratio (AT/BT) Function summary (Goterms or/and SP_PIR _KEYWORDS)
NCEH1 neutral cholesterol ester hydrolase 1 0.001 0.004 0.89 Lipid metabolism.
GO:
- Cholesterol ester hydrolase
- Lipid catabolic process
- Endoplasmic reticulum
ACSS2 Acyl-CoA synthetase short-chain family member 2 0.001 0.004 0.86 Lipid metabolism, Golgi apparatus. Synthesis of cholesterol and
unsaturated fatty acids.
Glycolysis/gluconeogenesis pathway.
GO:
- Protein binding
- Nucleotide binding
- Lipid biosynthetic process
- Nucleus
ANKRD17 Ankyrin repeat domain 17 0.001 0.002 0.95 Response to stress
AP1M1 Adaptor-related protein complex 1, mu 1 subunit 0.000 0.002 0.83 Medium chain of the trans-Golgi network clathrin-associated
protein complex AP-1.
Golgi apparatus. HIV-1 protein interactions with this gene
that is involved in HIV infection.
GO:
- Protein binding
- Intracellular protein transport
- Golgi apparatus
AQR Aquarius homolog 0.001 0.002 0.94 Nucleobase, nucleoside, nucleotide and nucleic acid metabolic
process, nucleic acid binding.
GO:
- RNA binding
- mRNA processing
- Spliceosomal complex
ARHGAP1 Rho GTPase activating protein 1 0.000 0.002 0.86 D4-GDI signalling pathway, Erk and PI-3 kinase. Immunology.
GO:
- Protein binding, GTPase activator activity
- Regulation of GTPase activity
- Plasma membrane
ASF1B ASF1 anti-silencing function 1 homolog B 0.001 0.002 0.93 Modulating the nucleosome structure of chromatin. Efﬁciency
of nucleosome assembly.
GO:
- Histone binding
- Chromatin assembly or disassembly, nucleosome assembly
- Chromatin
FAM110A Family with sequence similarity 110, member A 0.001 0.002 0.79 GO:
- Protein binding
- Centrosome
C2CD2 C2 calcium-dependent domain containing 2 0.000 0.002 0.89
CTDSP2 CTD (carboxy-terminal domain, RNA polymerase II,
polypeptide A) small phosphatase 2
0.001 0.002 0.76 Promoter clearance during steroid-activated transcription.
GO:
- Hydrolase activity
DUSP1 Dual speciﬁcity phosphatase 1 0.001 0.004 0.73 Response to stress. Non-receptor-type protein-tyrosine
phosphatase family.
Phosphatase activity, inactivates mitogen-activated protein
(MAP) kinase.
GO:
- MAP kinase tyrosine/serine/threonine phosphatase activity
- Intracellular signalling cascade, response to oxidative stress
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Table 1 (continued)
Gene symbol Genes description Parametric p-value Permutation p-value Intensities ratio (AT/BT) Function summary (Goterms or/and SP_PIR _KEYWORDS)
ERCC1 Excision repair cross-complementing rodent
repair deﬁciency, complementation group 1
0.0000 0.0020 0.93 Response to stress. Human DNA repair gene.
GO:
- Hydrolase activity, damaged DNA binding
- Response to oxidative stress, response to DNA damage stimulus
- Nuclear chromosome, telomeric region
ETV6 Ets variant gene 6 (TEL oncogene) 0.0001 0.0020 0.86 Hematopoiesis and maintenance of the developing vascular network.
GO:
- Protein domain speciﬁc binding, sequence-speciﬁc DNA binding
- Regulation of transcription, DNA-dependent
- Nucleus
DEF8 Differentially expressed in FDCP 8 homolog 0.0006 0.0039 0.87 GO:
- Diacylglycerol binding, zinc ion binding
- Intracellular signalling cascade
GALE UDP-galactose-4-epimerase 0.0006 0.0020 0.92 Galactose pathway.
Synthesis of glycoproteins and glycolipids.
GO:
- UDP-glucose-4-epimerase activity
- Galactose catabolic process
HCFC1 Host cell factor C1 0.0006 0.0020 0.83 Involved in control of the cell cycle and transcriptional
regulation during herpes
simplex virus infection.
GO:
- Transcription coactivator activity positive regulation of cell cycle
- Nucleus
HPS6 Hermansky–Pudlak syndrome 6 0.0005 0.0020 0.84 GO:
- Protein binding
- Blood coagulation, melanocyte differentiation, pigmentation
KIAA0513 KIAA0513 0.0001 0.0020 0.83
KLHDC3 Kelch domain containing 3 0.0001 0.0020 0.85 GO:
- Chromatin binding
- Reciprocal meiotic recombination
- Nuclear chromatin
TMEM179B Transmembrane protein 179B 0.0002 0.0039 0.89 GO:
- Integral to membrane
MAP3K6 Mitogen-activated protein kinase kinase kinase 6 0.0006 0.0020 0.90 Stress-activated protein kinase signalling pathway.
MAPK signalling pathway.
GO:
-Protein serine/threonine kinase activity, nucleotide binding
-Activation of JUN kinase activity
NFXL1 Nuclear transcription factor, X-box binding-like 1 0.0004 0.0020 0.90 GO:
- Metal ion binding, zinc ion binding
- Regulation of transcription, DNA-dependent
- Integral to membrane, nucleus
P2RY13 Purinergic receptor P2Y, G-protein coupled, 13 0.0001 0.0020 0.59 GO:
- G-protein coupled receptor activity
- G-protein coupled receptor protein signalling pathway
- Integral to membrane, endoplasmic reticulum
PAK4 p21(CDKN1A)-activated kinase 4 0.0006 0.0020 0.94 Golgi apparatus. Protein transport. Regulation of actin cytoskeleton.
GO:
- Protein serine/threonine kinase activity, nucleotide binding
- Protein amino acid phosphorylation
- Golgi apparatus
PEX11G Peroxisomal biogenesis factor 11 gamma 0.0003 0.0020 0.95 GO:
- Peroxisome ﬁssion
- Integral to membrane
(continued on next page)
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Table 1 (continued)
Gene symbol Genes description Parametric p-value Permutation p-value Intensities ratio (AT/BT) Function summary (Goterms or/and SP_PIR _KEYWORDS)
POLR3B Polymerase (RNA) III (DNA-directed) polypeptide B 0.0004 0.0039 0.91 Purine and pyrimidine metabolism. HIV-1 Tat up-regulates the
transcription by RNA polymerase III.
GO:
- Metal ion binding, zinc ion binding,
ribonucleoside binding
- Transcription
- Nucleus
PRAF2 PRA1 domain family, member 2 0.0002 0.0020 1.10 Golgi apparatus. Protein transport.
GO:
-L-glutamate transport
-Endosome, integral to membrane
SLC25A25 Solute carrier family 25
(mitochondrial carrier; phosphate carrier),
member 25
0.0005 0.0020 0.72 GO:
- Calcium ion binding
- Transport
- Integral to membrane, mitochondrial inner membrane
SPATA5L1 Spermatogenesis associated 5-like 1 0.0002 0.0020 1.14 GO:
- Nucleotide binding, nucleoside-triphosphatase activity
TBC1D14 TBC1 domain family, member 14 0.0005 0.0020 0.83 GO:
- GTPase activator activity
- Regulation of Rab GTPase activity
TERF1 Telomeric repeat binding factor
(NIMA-interacting) 1
0.0003 0.0020 1.14 Component of the telomere nucleoprotein complex,
inhibitor of telomerase.
GO:
- Negative regulation of telomerase activity
- Chromosome, nucleus
UTS2 Urotensin 2 0.0001 0.0020 1.08 Highly potent vasoconstrictor.
GO:
- Hormone activity
- Regulation of blood pressure, muscle contraction,
synaptic transmission
- Extracellular region
VASH1 Vasohibin 1 0.0003 0.0020 0.90 Angiogenesis inhibitor.
GO:
- Negative regulation of angiogenesis, negative
regulation of blood
vessel endothelial cell migration
- Endoplasmic reticulum, extracellular region
WNT10B Wingless-type MMTV
integration site family, member 10B
0.0001 0.0020 1.07 Adipogenesis.
GO:
- Wnt receptor signalling pathway, calcium
modulating pathway, multicellular
organismal development
- Extracellular region
ZFP106 Zinc ﬁnger protein 106 homolog 0.0001 0.0020 0.85 GO:
- Metal ion binding, zinc ion binding
- Insulin receptor signalling pathway
ZNF438 Zinc ﬁnger protein 438 0.0004 0.0020 0.85 GO:
- Metal ion binding, zinc ion binding
- Regulation of transcription
Annotation and gene expression information for the 36 candidate genes selected as differentially expressed in PBMC of healthy individuals after low-dose ritonavir treatment. BT: before treatment, AT: after treatment. AT/BT is the intensity ratio
between the two states. SP_PIR_KEYWORDS: Protein Information Resource (http://pir.georgetown.edu/) and Swissprot (http://www.expasy.ch/sprot/). Keywords retrieved with DAVID online tool (http://david.abcc.ncifcrf.gov/home.jsp).
GOterms: gene ontology terms.
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Table 2
Functional class scoring analysis following ritonavir treatment of PBMC gene.
GO
category
GO
term
GO description Number
of
genes
LS
permutation
p-value
KS
permutation
p-value
31497 BP Chromatin assembly 70 1.00E-05 6.30E-04
16055 BP Wnt receptor signalling
pathway
55 2.12E-03 4.50E-02
17038 BP Protein import 77 2.13E-03 1.24E-03
7031 BP Peroxisome organisation
and biogenesis
17 2.14E-03 1.20E-01
6471 BP Protein amino acid ADP-
ribosylation
29 2.52E-03 2.34E-03
9126 BP Purine nucleoside
monophosphate
metabolic process
15 4.51E-03 3.20E-02
42440 BP Pigment metabolic
process
24 6.70E-03 3.55E-03
7046 BP Ribosome biogenesis and
assembly
13 7.01E-03 1.32E-03
51049 BP Regulation of transport 41 1.01E-02 4.66E-03
6606 BP Protein import into
nucleus
64 1.49E-02 3.32E-03
16126 BP Sterol biosynthetic
process
26 1.95E-02 1.39E-03
51345 BP Positive regulation of
hydrolase activity
32 3.55E-02 2.17E-03
9311 BP Oligosaccharide
metabolic process
11 3.60E-02 2.33E-03
51223 BP Regulation of protein
transport
19 1.45E-01 3.52E-03
43241 BP Protein complex
disassembly
16 1.46E-01 2.98E-03
3899 MF DNA-directed RNA
polymerase activity
40 1.00E-05 1.00E-05
3950 MF NAD+ADP-
ribosyltransferase
activity
25 2.66E-03 9.69E-03
4726 MF Non-membrane
spanning protein
tyrosine phosphatase
activity
7 3.23E-03 2.35E-01
16857 MF Racemase and epimerase
activity\, acting on
carbohydrates and
derivatives
6 4.37E-03 5.14E-02
8094 MF DNA-dependent ATPase
activity
35 5.73E-02 2.31E-03
786 CC Nucleosome 47 1.00E-05 1.00E-05
44439 CC Peroxisomal part 23 1.76E-03 2.35E-02
228 CC Nuclear chromosome 48 1.91E-03 1.80E-02
30880 CC RNA polymerase
complex
25 3.49E-03 6.64E-03
43596 CC Nuclear replication fork 9 4.09E-03 3.23E-03
30027 CC Lamellipodium 12 2.40E-02 3.44E-03
Gene ontology classes that are differentially expressed before and after ritonavir
treatment were evaluated using a functional class scoring analysis (27). For each gene
in a GO class, the p-value for comparing pre versus post treatment samples was
computed. The set of p-values for a class was summarised by two summary statistics:
• LS = average log p-values for the genes in that class.
• KS = Kolmogorov–Smirnov statistic computed on the p-values for the genes in that
class.
Twenty six gene ontology classes were shown to be signiﬁcantly modiﬁed following
low-dose ritonavir treatment of volunteers PBMC. It is of interest to observe that certain
functional classes of genes, such as sterol biosynthesis process (26 genes), and
oligosaccharides metabolic process (11 genes), are signiﬁcantly affected in PBMC
following ritonavir treatment. Abbreviations: CC = Cellular Component, MF =
Molecular Function, BP= Biological Process.
61S. Yilmaz et al. / Genomics 96 (2010) 57–65genes in PBMC, respectively 62, 219, 55 for Random-variance t-test,
SAM and ANOVA, and their intersection showed a total of 36
candidate genes (Table 1). Five of these genes were up-regulated
and 31 were down-regulated in PBMC following ritonavir treatment.
It should be noted that 4 of these genes (ANKRD17, DUSP1, ERCC1,
MAP3K6) are implicated in stress response, 2 (NCEH1, ACSS2) in lipidmetabolism, 4 (ACSS2, AP1M1, PAK4, PRAF2) are functionally linked
with the Golgi apparatus, and 3 (ETV6, UTS2, VASH1) are associated
with the vascular network. Finally, 3 genes (NCEH1, P2RY13 and
VASH1) are functionally implicated in the endoplasmic reticulum. The
functions of the remaining 23 genes are shown in Table 1.
Functional class scoring
Functional class scoring analysis shows 26 Gene Ontology classes
that are signiﬁcantly altered (p-valueb0.005). A break up of these 26
classes shows that 15 are biological processes, 5 are molecular
functions and 6 are cellular components (Table 2). The biological
process, “chromatin assembly”, is observed to be signiﬁcantly affected
and show 27 histone genes that are signiﬁcantly up-regulated
following ritonavir treatment (Table 2). Moreover, histone gene up-
regulation was also represented in the cellular component “nucleo-
some”. DNA-directed RNA polymerase activity seems to deregulated
molecular processes that seem related. DUSP1 (ratio of 0.73, p-
value=5E-04) and KLHDC3 (ratio AT/BT=0.85, p-value=8E-05) are
the top scoring genes using this functional approach and are
implicated respectively in the molecular function “non-membrane
spanning protein tyrosine phosphatase activity” and in cellular
component “nuclear chromatin” (Fig. 1).
Selection of genes for further analysis by quantitative real time PCR (Q-PCR)
Several lines of evidence have drawn our attention to 2 candidate
genes, namely dual speciﬁcity phosphatase 1 (DUSP1), and Kelch
domain containing 3 (KLHDC3). Indeed, ﬁrstly these 2 genes belong to
the list of 36 candidate genes. Secondly, DUSP1 (ratio of 0.73) and
KLHDC3 (ratio AT/BT=0.85) are the top scoring genes using the
functional scoring approach. Moreover, 2 other genes, neutral
cholesterol ester hydrolase 1 (NCEH1) and acyl-CoA synthetase
short-chain family member 2 (ACSS2), belonging to the lipid
metabolism and related pathways and previously cited to be affected
by ritonavir in human and murine hepatocytes, were also selected
[7,8]. Q-PCR performed on 20 healthy individuals taking part in this
study conﬁrm that expression levels of all four candidate genes are
signiﬁcantly down-regulated for 100 mg of ritonavir given once daily
(Fig. 1A). Similar gene down-regulation results are observed when
100 mg of ritonavir is given twice daily for DUSP1, KLHDC3 and ACSS2
genes. Results for NCEH1 gene shows the same tendency with a p-
value of 0.09 (Fig. 1B). The Q-PCR results validate the data obtained
using microarrays for the 4 genes.
Pathway analysis
Cytoscape (http://www.cytoscape.org/) software programme
was used to investigate links between the four selected genes
ACSS2, NCEH1, DUSP1 and KLHDC3 genes. An intermediate gene that
link DUSP1 and KLHDC3 has been found. Indeed, DUSP1 is linked to
SKP2 and CUL1 [11]. Moreover, CUL1 is linked on the one hand toMCC
and CUL2 [12] and on the other to CAND1 [13,14] which itself is linked
to CUL2 [13,15]. Finally, KLHDC3 is linked to CUL2 via DLG3 [12]
(Fig. 2).
Discussion
This study shows for the ﬁrst time a signiﬁcant effect of low-dose
ritonavir on the modulation of the expression of genes in PBMC of
healthy volunteers. Several lines of evidence are presented to show
the effects of ritonavir on circulating PBMC: (1) thirty six candidate
genes are shown to be signiﬁcantly modulated by ritonavir. Indeed,
stress response, nucleic acid binding, lipid metabolism, Golgi
apparatus and vascular network genes present among the 36
candidates are affected by ritonavir. (2) Four genes out of these 36
Fig. 1. Q-PCR validation of DUSP1, KLHDC, NCEH1 and ACSS2 genes in PBMC isolated from healthy volunteers before treatment (BT) and after treatment (AT) with low-dose ritonavir.
Boxplot of Q-PCR results at BT and AT using total RNA extracted from PBMC from 20 volunteers (p-valueb0.05, Student paired t-test). A: group receiving 100 mg of ritonavir once
daily and B: the group receiving 100 mg of ritonavir twice daily.
62 S. Yilmaz et al. / Genomics 96 (2010) 57–65genes, ACSS2, NCEH1, DUSP1, and KLHDC3, were shown by Q-PCR in 20
healthy individuals to be signiﬁcantly down-regulated by ritonavir.
(3) Functional class scoring analysis shows 26 Gene Ontology classes
that are signiﬁcantly altered and that ritonavir signiﬁcantly up-
regulates histone families.
In this study, ritonavir is observed to signiﬁcantly down-regulate
stress related gene families such as dual speciﬁcity phosphatase 1
(DUSP1), excision repair cross-complementing rodent repair deﬁ-
ciency, complementation group 1 (ERCC1), ANKRD17 (ankyrin repeat
domain 17), and mitogen-activated protein kinase kinase kinase 6(MAP3K6) (Table 1). It should be noted that previous work equally
identiﬁed stress related genes in murine adipocytes to be affected
following ritonavir treatment [7]. Three genes (ETV6, UTS2, and
VASH1) are associated with the vascular network. ETV6 is known
implicated in haematopoiesis and maintenance of the developing
vascular network, UTS2 is a highly potent vasoconstrictor and ﬁnally
VASH1 acts as a negative regulation of angiogenesis. Four genes,
AP1M1, ACSS2, PAK4, PRAF2 affected by ritonavir are functionally
linked with the Golgi apparatus. AP1M1 gene is part of AP-1 complex
located at the Golgi vesicle and involved in endocytosis and Golgi
Fig. 2. Genes linking DUSP1 gene and KLHDC3. DUSP1 and KLHDC3 genes are linked through a number of intermediary genes that include CUL1,MCC, CUL2, DLG3 and CAND1. Please
note that CUL1 and CUL2 are connected either via CAND1 or MCC. Moreover, DUSP1 is connected to CUL1 and SKP2. It is of interest to see that DLG3 is linked to both ABCA1 and
HIST1H2BC. These molecules are all part of molecular complexes or are in direct physical interaction. The evidences of the associations were either produced by
coimmunoprecipitation, X-ray crystallography, afﬁnity chromatography technology, peptide array or enzymatic study. The IntAct database identiﬁcation number is indicated for
each gene of the pathway.
63S. Yilmaz et al. / Genomics 96 (2010) 57–65processing. Some authors suggested that proper post-Golgi routing of
HIV Env protein depends on its recruitment of AP-1 [16]. Down-
regulation of AP-1 could conceivably inhibit endocytosis of HIV.
POLR3B is also known to interact with HIV proteins [17]. POLR3B is
used by HIV-1 Tat protein to up-regulate viral transcription [18].
Lipid metabolism and related pathways have been reported to be
modulated by ritonavir treatment in murine adipocytes [7,8,10] and
in human hepatocytes [8]. In this study, lipids were observed to be
affected by the ritonavir treatment. Indeed, high-density lipoprotein
(HDL) were shown to be decreased by ritonavir 100 mg once daily
(6%, p=0.01) or 100 mg twice daily (10%, p=0.001). Triglyceride
levels were observed to increase (32%, p=0.044) following ritonavir
(100 mg twice daily) [6]. Genes, neutral cholesterol ester hydrolase 1
(NCEH1) and acyl-CoA synthetase short-chain family member 2
(ACSS2), that belong to the lipid metabolism and related pathways,
which include cholesterol and fatty acid biosynthesis are down-
regulated in PBMC. The NCEH1 gene, also known as KIAA1363 and
NCEH1 (neutral cholesterol ester hydrolase 1), is a central node kin
and an ether lipid signalling network that bridges platelet-activating
factor and lysophosphatidic acid [19]. It should be noted that NCEH1
gene has been presented as potential therapeutic target for the
prevention of atherosclerosis. Indeed, RNA silencing of NCEH1
decreases neutral cholesterol ester hydrolase activity at least by 50%
whereas over expression of NCEH1 gene inhibits the cholesterol ester
formation in macrophages. In our study, it is conceivable that NCEH1
down-regulation, following ritonavir treatment, increases the risk of
atherosclerosis [20].
The ACSS2 gene is implicated in various pathways including lipid
biosynthetic process, glycolysis/gluconeogenesis pathways and bio-
logical oxidation via the reduction of carboxylate cycle. ACSS2 encodes
a cytosolic enzyme that catalyses the activation of acetate for use in
lipid synthesis and energy generation. Expression of this gene is
regulated by sterol regulatory element-binding proteins, transcription
factors that activate genes required for the synthesis of cholesterol
and unsaturated fatty acids. Thus, this gene may act at the interface
between lipid, glucose and oxidative stress metabolisms (http://
www.ncbi.nlm.nih.gov/sites/entrez?db=gene). ACSS2 and NCEH1
activities are held within the endoplasmic reticulum, a cellular
component that has been previously implicated in lipid disorders
associated with ritonavir treatment [7,8].
Previous studies performed on human hepatocytes and murine
adipocytes have reported an effect of ritonavir on the endoplasmic
reticulum and ER stress response of these cells [7,8]. Interestingly, our
results show 3 genes (NCEH1, P2RY13, VASH1), implicated in the
endoplasmic reticulum, to be affected by ritonavir. Moreover, an
oxidative stress response is shown through the ERCC1 and DUSP1
genes. Adler-Wales et al. in linewith the current results also reported the
implication of oxidative stress after ritonavir treatment [5]. Theproteasome following ritonavir treatment is described by Lum et al. to
beup-regulated in rat liver anddown-regulated inhumanhepatocytes as
observed by Parker et al. [8,10]. The current study does not observe any
modulation of the proteosome in PBMC following ritonavir treatment.
Dual speciﬁcity phosphatase 1 (DUSP1) has very recently been
shown to play a major role in inﬂammation and atherosclerosis [21].
Indeed, Zakkar et al. have demonstrated that DUSP1 has an anti-
inﬂammatory effect by suppressing p38 and MAPK8. Induction of
DUSP1 appears to be essential in protecting atherosclerosis regions. It
is of interest to note that DUSP1-deﬁcient macrophages showed
selectively prolonged activation of MAPK14 and increased cytokine
production. Gene silencing of DUSP1 restored VCAM1 expression, a
well knownmarker of atherosclerosis [21]. One should note that there
is a certain amount of controversy on the role of DUSP1 in
atherosclerosis. Indeed, Kang et al., reported that DUSP1 was one of
the two most cited genes (the other one being FOS: v-fos FBJ murine
osteosarcoma viral oncogene homolog) that are up-regulated in
patients with atherosclerosis compared to controls [22]. In the current
study, DUSP1 is signiﬁcantly down-regulated in PBMCs of healthy
volunteers treated with low-dose ritonavir. Down-regulation of
DUSP1 by low-dose ritonavir may conceivably lower the protection
of certain sites that are resistant to atherosclerosis.
The other gene that is down-regulated by low-dose ritonavir in
PBMC is Kelch domain containing 3 (KLHDC3), about which little is
currently known. The protein encoded by this gene, bears six repeated
Kelchmotifs, and is involved in meiotic recombination. Moreover, this
protein appears to be involved in V (D)J recombination and to be
expressed speciﬁcally in the testis [23]. A homolog of KLHDC3,
Drosophila ring canal Kelch protein, is related to galactose oxidase, an
enzyme that cleaves galactose [24]. DUSP1 and KLHDC3 genes are
linked through a number of intermediary genes (Fig. 2). One of these
intermediary linking genes, CUL2, is required for the activity of
vasculogenesis and hypoxia-inducible factor [25,26]. The other, ATP-
binding cassette (ABC) transporters (ABCA1), functions as a choles-
terol efﬂux pump in macrophages. These molecules are all part of
molecular complexes or are in direct physical interaction. The
evidence of the association was either produced by coimmunopreci-
pitation, X-ray crystallography, afﬁnity chromatography technology,
peptide array or enzymatic study. We expected to see with the down-
regulation of DUSP1 a certain number of genes that are linked with it
such as S-phase kinase-associated protein 2 (SKP2) or cullin 1 (CUL1)
to be also differentially expressed. However, we have not observed a
differential expression of these genes. It is conceivable that 14 days of
modulation by low-dose ritonavir (100 mg twice daily) is not
sufﬁcient to affect DUSP1 related pathways.
Functional class scoring is based on gene ontology, a controlled
and organised vocabulary that describes molecular function, biolog-
ical process and cellular component of genes products [27,28].
64 S. Yilmaz et al. / Genomics 96 (2010) 57–65Detailed analysis of affected functional classes (cellular component,
molecular function and biological process) is an alternative powerful
way to search for candidate genes affected by low-dose ritonavir in
circulating volunteer's PBMC. In our experiments, the nucleosome
class (containing a total of 47 genes) is signiﬁcantly affected by low-
dose ritonavir. The nucleosome class and nuclear chromatin class are
part of the chromatin class (Fig. 1). In the nuclear chromatin class the
most signiﬁcantly affected genes is KLHDC3 (see Table 2). It is after
this observation that we selected the KLHDC3 gene as a candidate to
be tested by Q-PCR.
In conclusion, our investigation on PBMC gene expression,
following low-dose ritonavir treatment in healthy donors, shows a
signiﬁcant change in the expression of 36 genes.
To our knowledge this is the only study performed with healthy
volunteers that shows for the ﬁrst time the effect of low-dose
ritonavir on gene expression and biological functions in PBMC that
may potentially be implicated in inducing metabolic abnormalities
and cardiovascular disease. Lower expression levels of DUSP1, a gene
known to play a critical role in preventing inﬂammation and
atherosclerosis, and NCEH1, a gene critically involved in ether lipid
signalling network that bridges platelet-activating factor and lysopho-
sphatidic acid, may be some of the factors related to Ritonavir's
adverse effects. Such a study provides a powerful combination of
tools, using circulating blood cells in tandemwith microarrays and Q-
PCR, to investigate the secondary effects of ritonavir on treated
patients. Generated data obtained by investigating the gene expres-
sion levels of circulating PBMC may greatly help in identifying critical
genes implicated in the side effects of ritonavir.Material and methods
Subjects
Male (n=10) and female (n=10) healthy volunteers between 18
and 45 years of age (age matched) were enrolled in this study after
giving fully informed and written consent. Subjects were excluded if
they had: (1) a history of cigarette smoking or cardiovascular disease,
(2) any active clinically signiﬁcant disease, and (3) been taking any
medication or herbal remedy up to 14 days before screening.Study design
In this study, 2 doses of ritonavir (100 mg once or twice daily,
commonly used as boosting doses) were investigated [6]. Eligible
subjects were randomised into 2 groups (arm1 and arm2). Indeed,
subjects in arm 1 received ritonavir 100 mg orally once daily (o.d.) for
14 days (days 1 to 14) followed by a 14 day-washout period (days 14 to
30) and then ritonavir 100 mg twice daily (b.i.d.) for 14 days (days 30 to
43). Subjects in arm 2 received ritonavir 100 mg twice daily for 14 days,
followed by a 14 day-washout period and by ritonavir 100 mg once
daily. Blood was drawn before and after treatment or washout periods
for all the subjects (arm1 and 2). PBMCs samples from 5 males and 5
females following 100 mg twice daily ritonavir treatment (from arm 1
and 2)were used for themicroarray study, whereas all the subjects and
bothdoses (ritonavir 100 mgo.d. andb.i.d.)were investigatedbyQ-PCR.
This study was approved by the Riverside Research Ethics Committee,
London, UK. The tolerability and safety of ritonavir were evaluated
throughout the study.Processing of blood samples
Peripheral blood mononuclear cells (PBMC) were isolated from
50mL blood using Ficoll gradient and stored in RNALater at−20 °C until
sample extraction.Microarrays investigations
RNA samples
PBMCs were thoroughly washed in sterile PBS twice to eliminate
traces of RNALater. Total RNA was isolated using the RNeasy mini kit
(Qiagen, West Sussex, UK) according to the manufacturer's instruc-
tions. Total RNA quantity and integrity were assayed using the
Nanodrop ND-1000 (Thermoscientiﬁc, Wilmington, DE, USA) and the
Agilent 2100 Bioanalyzer (Agilent technology, Palo Alto, CA, USA).
Illumina BeadChips
Samples were processed and data acquired by the microarray core
facility of Cambridge University (http://www.path.cam.ac.uk/
resources/microarray/) using Sentrix HumanRef8 BeadChips. Brieﬂy,
labelled cRNA were prepared using the Illumina RNA ampliﬁcation kit
(Ambion, Austin, TX). The twenty cRNA targets were hybridised to
Sentrix human Ref 8 BeadChips, which were scanned on an Illumina
BeadStation. Image processing and raw data extraction were
performed using the Illumina Beadstudio software. MIAME compliant
raw data obtained from all 20 microarrays were deposited at EBI,
ArrayExpress repository, under accession number E-TABM-642.
Background adjustment, probe ﬁltering and normalisation
Quality control and pre-processing were performed using the R
package lumi (http://www.bioconductor.org/packages/2.2/bioc/
html/lumi.html).
A total of 14,596 genes passed the ﬁltering process. We used a
Detection Score≥0.99 from the Illumina data as our criteria for a gene
to be considered expressed. Model-based variance-stabilising trans-
formation [29] and spline normalisation were followed by microarray
quality controls. Boxplot of microarray intensities shows equal mean
and variance across samples. Moreover, the density plot shows that
the distributions of intensities are identical across all samples.
Differential expression analysis
Differential expression analysis was performed using BRB-Array-
Tools developed by Dr. Richard Simon and BRB-ArrayTools Develop-
ment Team (http://linus.nci.nih.gov/BRB-ArrayTools.html). We
identiﬁed genes that were differentially expressed among the two
classes using a random-variance t-test for paired samples [30]. Genes
were considered signiﬁcantly altered if their p-value was less than
0.001. We also performed a global test of whether the expression
proﬁles differed between the classes by permuting the labels of which
arrays corresponded to which classes (BRB Manual, Sample Statistical
Methods Descriptions). Signiﬁcance Analysis of Microarrays (SAM)
was used with a target proportion of false discoveries of 0.15. Analysis
of variance (ANOVA) for Mixed Effects Model was used to select genes
that are differentially expressed by the factor “treatment” and not by
the factor “gender”.
Functional class scoring
The functional class scoring analysis for Gene Ontology (GO)
classes was performed as described by Palvidis et al. [31] and using
BRB-ArrayTools. This approach provides a list of differentially
expressed gene ontology classes between before-treatment and
after-treatment samples. Functional class scoring analysis evaluates
GO categories that are differentially expressed among different
phenotype classes 1. It demonstrates an improved technique for
identifying differentially expressed gene classes than traditional over-
representation analysis.
For each GO group a number of N genes representing the group on
themicroarray, the statistical signiﬁcance pi value for each gene i in the
group is calculated, that reﬂects the differential expression among
classes. Two statistics; the Fisher (LS) statistic and the Kolmogorov–
65S. Yilmaz et al. / Genomics 96 (2010) 57–65Smirnov (KS) statistic have been computed for each GO group that
summarised the p-values for genes in the group. The selection of N
random genes and p-value summarisation are repeated 100,000 times
to obtain a distribution of the statistics. Then, the LS (KS) permutation p-
value is deﬁned as the proportion of selections for each GO category, for
which the LS (KS) statistic has a value larger than the LS (KS) statistics
computed for the GO category with original gene list. A GO category is
selected as differentially expressed if its corresponding LS or KS re-
sampling p-value is below the threshold speciﬁed by the user (default is
0.005) (BRB Manual, Sample Statistical Methods Descriptions).
Pathway analysis
Construction of biological pathway was performed using Cytos-
cape software package available at http://cytoscape.org/. Cytoscape
is an open source bioinformatics software that permit the visualisa-
tion of biological pathways integrating public databases and gene
expression [32].
Real time quantitative PCR (Q-PCR)
Microarray differentially expressed gene results (DUSP1, KLHDC,
NCEH1 and ACSS2) were validated by Q-PCR using TaqMan® assays
(Applied Biosystems). Each ampliﬁcation was run in duplicates,
following retro-transcription of 100 ng/assay of total RNA isolated
from 20 healthy subjects. Data were normalised using 18S rRNA. Q-
PCR TaqMan® probes were selected to be as similar as possible to
those present on Illumina microarrays.
Statistical analysis for real time Q-PCR
Paired Student t-test was performed and a difference between
groups of patients before and after treatment was considered
signiﬁcant when pb0.05. The analyses were performed separately
for the group receiving 100 mg of ritonavir once daily and the group
receiving 100 mg of ritonavir twice daily.
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